Nowak-Göttl, Ulrike <br/><br/>
In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.  [electronic resource] 

 -  Blood  Dec 2010 
 - 6101-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2010-05-283861  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Age Factors<br/>Anticoagulants--administration & dosage<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Child<br/>Child, Preschool<br/>Cohort Studies<br/>Cytochrome P-450 CYP2C9<br/>Genotype<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Mixed Function Oxygenases--genetics<br/>Phenprocoumon--administration & dosage<br/>Polymorphism, Genetic--genetics<br/>Prognosis<br/>Prospective Studies<br/>Thrombosis--drug therapy<br/>Vitamin K--antagonists & inhibitors<br/>Vitamin K Epoxide Reductases<br/>Warfarin--administration & dosage<br/>Young Adult